PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
January 25, 2026ESMO Open2 citationsOpen Access

Camizestrant in combination with capivasertib for women with ER-positive, HER2-negative advanced breast cancer: results from SERENA-1

View Full Paper
CVChristos VaklavasMOM. OliveiraAAAC Armstrong

Key Points

  • The study aims to evaluate the effectiveness and tolerability of camizestrant combined with capivasertib in women with advanced breast cancer.
  • Evaluated pretreated participants
  • Administered camizestrant 75 mg and capivasertib 400 mg
  • Monitored side effects
  • Assessed clinical efficacy
  • Treatment was well tolerated
  • Side effects were consistent with each drug as monotherapy
  • Showed encouraging evidence of clinical efficacy

Abstract

In these pretreated participants, camizestrant 75 mg in combination with capivasertib 400 mg was well tolerated, with a side effect profile consistent with each drug as monotherapy, and showed encouraging evidence of clinical efficacy.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Vaklavas et al. (2026) studied this question.

synapsesocial.com/papers/6975b2c8feba4585c2d6e4b0https://doi.org/10.1016/j.esmoop.2025.106049
Ask AI
Helpful
Bookmark
Share
View Full Paper